Tysabri: Attention must be paid.

  • by: |
  • 03/07/2006

An important, timely, and on-target editorial from today’s edition of the Washington Times. Attention must be paid.

Today, an advisory committee to the Food and Drug Administration will review information and hear from patients about whether to permit a medicine for multiple sclerosis called Tysabri back onto the market after a year’s absence. The FDA approved Tysabri in November 2004 after only year of clinical trials.

The agency did so because the drug worked extremely well in stopping what are known as “relapses,” a diplomatic term for describing the loss of memory, the inability to walk and permanent disability that occurs when the protective insulation of the nerves necessary for healthy brain function, and then the nerves themselves, are slowly destroyed. And compared to other MS drugs, Tysabri appeared to have few side effects.

Last February, Tysabri was voluntarily withdrawn from the market after someone taking it in combination with Avonex, another MS drug, died from progressive mulitfocal leukoecephalopathy (PML), a rare neurological disease. Another patient suspected of having PML at that time was later confirmed. An exhaustive study of all patients who took the drug found no new cases of PML. Overall, there is a 0.1 percent risk of contracting PML if you use Tysabri. That’s half the risk of dying from aspirin. Meanwhile, MS causes about 53,000 relapses yearly and 5 percent of relapses cripple or kill their victims.

Too often, in the wake of Vioxx withdrawal, pundits have ignored the health risks of not making a medicine available. Those risks cannot be ignored in this case. All the information about Tysabri’s benefits and risk are available. A plan is in place to reduce risk further and determine the best treatment strategy for every patient. MS patients have taken a page from HIV/AIDS activists and are descending on the hearing en masse. Their message: Our lives, our choice. Let’s hope the FDA and its advisory committee listen with open hearts and minds.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog